Companion bills in the Massachusetts House and Senate would restore the 340B program’s intent by stopping pharmacy benefit manager discrimination against any 340B covered entities and their contract pharmacies, the sponsor of the state Senate bill said during a recent
…
With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.
Slafsky, publisher and CEO of 340B
…
SPONSORED CONTENT
In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary syphilis to less than 2.2 cases per 100,000 population, congenital syphilis to less than 3.9 cases per 100,000, and the racial disparity between rates of syphilis among Black and White individuals to less than 3:1. Despite having moderate success at the turn of the century, the US is experiencing a drastic resurgence of syphilis. In 2021, the CDC reported 171,074 total cases of syphilis nationally, a 68.4% increase from 2017. Worse, there has been a sharp increase in the number of babies born with syphilis; cases of congenital syphilis rose 184.5% to 2,677 cases between 2017 and 2021.
Like other sexually transmitted infections (STIs), syphilis disparities remain with regards to
…
In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program and provide the best care to those they serve.
About our guest, Ted Slafsky:
Publisher and Chief Executive Officer of 340B Report, Ted is a long-time healthcare thought leader and journalist. He is the Founder & Principal of Wexford Solutions LLC, has three decades of experience in 340B and journalism.
SPONSORED CONTENT
Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings and hopes for the best, the exclusions are harming patients’ ability to access vital medications and safety net services and delivering a serious blow to hospital and other 340B covered entity finances.
Healthcare providers can’t wait around and count on help from the courts, Congress, or the Biden administration. They need options, now, to restore their margins and ensure they can continue to serve their most vulnerable patients.
At The Craneware Group, we’ve been writing about ways covered entities can regain ground lost to the drug manufacturers and their unlawful actions. We’ve also been evaluating the utilization of biosimilars. By closely examining the 19 manufacturers restricting 340B pricing
…
A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.
Number two on the list (based on how often a story page
…
Medicare likely would pay 340B hospitals 106% of the average sales price (ASP) for Aduhelm—Biogen’s high-cost biologic drug for early-stage Alzheimer’s disease—for the first two or three years it is on the market, not the ASP minus 22.5% 340B hospital
…
Q: Where did you grow up?
Minneapolis, MN
Q: Where did you go to college/graduate school?
I received my undergraduate degree received from University of
…SPONSORED CONTENT
This strategy could save the 340B proceeds at your organization
Today, underinsured or uninsured patients who are undergoing treatment with a Gilead HIV treatment or preventative medication may be eligible to receive those medications at no cost through Gilead’s Advancing Access program. Under this program, covered entities are able to receive full 340B proceeds from these dispenses and can use these funds to support and expand critical community programs and outreach efforts.
As most Ryan White and STI grantee covered entities probably are aware, on January 1, 2022, Gilead will no longer reimburse pharmacies at full retail price under its Advancing Access program. This will eliminate nearly all the 340B proceeds you may be currently receiving under this program and could have a huge impact on your business and the
…
Q: Where did you grow up?
Born and raised in the great state of Iowa, and I still live here. It is a fantastic place to raise a
…*Sign up for news summaries and alerts from 340B Report
